Table 1. Clinical development pipeline of nAChR and 5-HT₃R ligands.

nAChR
Compound	Classification	Indications	Development status	Reference
Nicotine	agonist	Smoking cessation	Marketed	73
Cytisine	agonist	Smoking cessation	Marketed	74
Bupropion	antagonist	Smoking cessation	Marketed	75
Varenicline	agonist	Smoking cessation	Marketed	76
CP-601927	agonist	Smoking cessation	Phase 2	77
Pozanicline	agonist	ADHD	Phase 3	78
Sofinicline	agonist	ADHD	Phase 2	79
Altinicline	agonist	Parkinson	Phase 2	80
GTS-21	antagonist	Alzheimer	Phase 2	81

5-HT3R
Compound	Classification	Indications	Development status	Reference
Alosetron	antagonist	IBS	Marketed	82
Granisetron	antagonist	Antiemetic	Marketed	83
Tropisetron	antagonist	Antiemetic	Marketed	84
Ondansetron	antagonist	Antiemetic	Marketed	85
Metoclopramide	antagonist	Antiemetic	Marketed	85

ADHD, attention deficit hyperactivity disorder; IBS, irritable bowel syndrome.